工程化益生菌用于肿瘤靶向联合化学免疫治疗
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.
我们的方法将酶/前药治疗和免疫治疗整合到一个单一的细菌递送系统中,通过提供合理设计的空间控制化学免疫治疗框架,克服了传统疗法的关键局限性。
英文原题:The niche-metabolism axis: reprogramming tumor-associated macrophages for precision immunotherapy.
肿瘤相关巨噬细胞(TAMs)关键性地调控实体瘤进展和免疫治疗耐药,然而其深刻的背景依赖性异质性无法用传统的M1/M2二分法来概括。
肿瘤相关巨噬细胞(TAMs)对实体瘤进展和免疫治疗耐药具有关键调控作用,然而其深刻的背景依赖性异质性无法用传统的M1/M2二分法加以概括。在本综述中,我们提出“生态位-代谢轴”框架,将肿瘤微环境解构为动态相互作用的功能性生态位(如缺氧核心和三級淋巴结构)。在这些生态位内,特定的物理化学应激显著影响局部TAM的代谢重编程。乳酸和脂质等代谢物不仅作为底物,还作为信号介质和表观遗传供体,塑造TAM表型。因此,TAM获得空间代谢印记,并演变为主动重塑免疫微环境的“生态系统工程师”。该框架强调,治疗范式应从非选择性TAM清除转向生态位特异性代谢-表观遗传重建,为设计下一代工程化巨噬细胞疗法提供精准路线图。
Tumor-associated macrophages (TAMs) critically modulate solid tumor progression and immunotherapy resistance, yet their profound context-dependent heterogeneity defies the traditional M1/M2 dichotomy. In this review, we propose the 'niche-metabolism axis' framework, deconstructing the tumor microenvironment into dynamically interacting functional niches (e.g., hypoxic cores and tertiary lymphoid structures). Within these niches, specific physicochemical stresses substantially influence localized TAM metabolic reprogramming. Metabolites such as lactate and lipids act not merely as substrates but as signaling mediators and epigenetic donors, shaping TAM phenotypes. Consequently, TAMs acquire spatial metabolic imprints and evolve into 'ecosystem engineers' that actively remodel the immune microenvironment. This framework highlights that therapeutic paradigms should shift from nonselective TAM depletion to niche-specific metabolic-epigenetic reconstruction, providing a precise roadmap for designing next-generation engineered macrophage therapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。